Cytokinetics (CYTK) Q3 FY2026 earnings: revenue $48 million, up 2356.5% on the year

Cytokinetics Inc. (CYTK) reported revenue of $48 million for Q3 FY2026, the quarter ended 30 September 2026, up 2356.5% on the same quarter a year earlier. Net income was -$190 million, and diluted earnings per share $-1.37. The figures are the company's own, from the 10-Q it filed with the SEC on 4 November 2026.

Revenue

$48 million

+2,356.5% on the year · +66.1% on the quarter

Q4 FY2024Q3 FY2026

Operating margin

-351.3%

-8613.4% a year earlier

Q4 FY2024Q3 FY2026

Net income

-$190 million

Q4 FY2024Q3 FY2026

Diluted EPS

-$1.37

Q4 FY2024Q3 FY2026

this quarterthe same quarter a year earlierHover a bar for its figure.

What management said

Guidance figures: 2 kept.

Total revenue rose on MYQORZO sales: Total revenues were $47.6 million, of which $44.5 million was MYQORZO net product revenue and $3.1 million was collaboration revenue. No license or milestone revenue was reported in the quarter.
Net loss lower than a year earlier: Net loss was $190.1 million, or $(1.37) per share, against $306.2 million, or $(2.55) per share, a year earlier. The year-earlier period included $121.2 million of debt conversion expense.
U.S. drove most product revenue: Of the $44.5 million net product revenue, $43.1 million came from the U.S. and $1.4 million from Europe, which reflects product revenue in Germany.

Read the earnings call summary

Income statement (profit and loss)

$ million	Q3 FY2026	Q2 FY2026	Q3 FY2025	On the quarter	On the year
Revenue	47.6	28.6	1.9	+66.1%	+2,356.5%
Research and development	99.3	97.8	97.3	+1.5%	+2.0%
Selling, general and administrative	113	104	69.5	+8.4%	+62.9%
Operating income	-167	-179	-167
Operating margin	-351.3%	-626.0%	-8613.4%
Interest expense	n/a	n/a	11.4
Net income	-190	-199	-306
Net margin	-399.7%	-694.4%	-15815.0%
Diluted EPS	-$1.37	-$1.50	-$2.55

$ million except per share.

Free cash flow is operating cash flow less capital expenditure; the effective tax rate is income tax over pre-tax income; margins are the line over revenue. Gross profit is revenue less cost of revenue, and operating income is revenue less the company's own total costs, where the statement does not print those lines. Those four are arithmetic on the filed numbers; everything else is as filed. Money is in $ million as the company files it, or in $ billion by the switch above the tables; per share figures and share counts are as they are. A quarter marked † is shown as the company last restated it in a later filing, so it compares with the quarters around it on one basis; rest on a figure for the one first filed. EPS is as filed.

Cash flow

$ million	Q3 FY2026	Q2 FY2026	Q3 FY2025	On the quarter	On the year
Operating cash flow	-124	-160	-108
Capital expenditure	0.7	4.3	9.4	-83.8%	-92.5%
Free cash flow	-125	-164	-117
Free cash flow margin	-262.3%	-573.6%	-6036.1%
Cash from investing	67.9	-507	-71.0
Cash from financing	4.8	793	330	-99.4%	-98.5%
Depreciation and amortisation	3.6	3.6	2.7	+0.5%	+36.2%
Share-based compensation	34.7	35.7	30.7	-2.8%	+13.1%
Diluted shares, weighted	139m	132m	120m	+5.3%	+15.9%
Shares outstanding at period end	139m	139m	122m	+0.2%	+13.9%

Cash flow lines for the quarter; where the company files them year to date, the quarter is the difference between two filings.

Balance sheet

$ million	Q3 FY2026	Q2 FY2026	Q3 FY2025	On the quarter	On the year
Shareholders' equity	-321	-173	-521
Debt	1,152	1,147	1,066	+0.4%	+8.1%
Operating lease liabilities	99.7	102	111	-2.7%	-9.9%
Other liabilities	895	849	781	+5.5%	+14.5%
Total liabilities and equity	1,825	1,925	1,437	-5.2%	+27.0%
Fixed assets	76.1	78.9	76.0	-3.5%	+0.2%
Investments	1,380	1,449	1,026	-4.7%	+34.5%
Cash and equivalents	203	255	225	-20.3%	-9.8%
Receivables	33.9	24.4	1.8	+38.7%	+1,774.4%
Inventory	0.8	0.4	n/a	+112.4%
Other assets	130	117	107	+11.5%	+21.3%
Total assets	1,825	1,925	1,437	-5.2%	+27.0%

Questions

What was Cytokinetics' revenue in Q3 FY2026?

Cytokinetics (CYTK) reported revenue of $48 million for Q3 FY2026, the quarter ended 30 September 2026, up 2356.5% on the same quarter a year earlier.

How much did Cytokinetics earn in Q3 FY2026?

Net loss for Q3 FY2026 was $190 million, and the diluted loss per share $1.37.

When did Cytokinetics report Q3 FY2026 results?

Cytokinetics filed its 10-Q for the quarter ended 30 September 2026 with the SEC on 4 November 2026.

Quarterly results, the last 20 quarters

	Q4 FY2021 *	Q1 FY2022	Q2 FY2022	Q3 FY2022	Q4 FY2022 *	Q1 FY2023	Q2 FY2023	Q3 FY2023	Q4 FY2023 *	Q1 FY2024	Q2 FY2024	Q3 FY2024	Q4 FY2024 *	Q1 FY2025 †	Q2 FY2025 †	Q3 FY2025 †	Q4 FY2025 *	Q1 FY2026	Q2 FY2026	Q3 FY2026
Revenue	55.6	1.1	89.0	2.5	2.0	4.6	0.9	0.4	1.7	0.8	0.2	0.5	16.9	1.6	66.8	1.9	17.8	19.4	28.6	47.6
R&D	43.5	45.9	57.1	62.7	75.0	79.4	83.2	82.5	85.0	81.6	79.6	84.6	93.6	98.3	110	97.3	104	95.5	97.8	99.3
SG&A	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	57.4	65.7	69.5	n/a	105	104	113
Operating income	-21.7	-77.9	-10.9	-108	-127	-124	-122	-122	-127	-126	-130	-141	-139	-156	-112	-167	-178	-184	-179	-167
Operating margin	-39%	-6782%	-12%	-4312%	-6491%	-2698%	-14077%	-32345%	-7621%	-15118%	-52278%	-30411%	-821%	-9856%	-167%	-8613%	-1005%	-949%	-626%	-351%
Interest expense	4.2	2.7	2.8	6.8	7.1	7.0	7.0	7.1	7.2	7.1	12.7	8.9	8.9	n/a	11.1	11.4	n/a	n/a	n/a	n/a
Net income	-30.6	-89.4	-19.8	-142	-137	-131	-129	-129	-137	-136	-143	-161	-150	-161	-134	-306	-183	-206	-199	-190
Net margin	-55%	-7791%	-22%	-5658%	-7020%	-2846%	-14837%	-34239%	-8188%	-16245%	-57557%	-34675%	-886%	-10220%	-201%	-15815%	-1031%	-1064%	-694%	-400%
Diluted EPS	-$0.33	-$1.05	-$0.23	-$1.52	n/a	-$1.38	-$1.34	-$1.35	-$1.38	-$1.33	-$1.31	-$1.36	-$1.26	-$1.36	-$1.12	-$2.55	-$1.50	-$1.67	-$1.50	-$1.37
Operating cash flow	-44.7	-26.8	-90.5	-84.0	-98.2	-122	-122	-96.2	-74.0	-130	-99.3	-102	-65.6	-132	-128	-108	-143	-145	-160	-124
Capital expenditure	17.8	0.9	0.9	6.3	3.2	0.4	0.7	0.2	0.1	0.0	1.9	0.7	1.3	5.7	4.1	9.4	5.6	5.9	4.3	0.7
Free cash flow	-62.5	-27.8	-91.3	-90.4	-101	-123	-123	-96.4	-74.1	-130	-101	-102	-66.9	-137	-132	-117	-148	-151	-164	-125
Shares outstanding	85m	86m	94m	95m	95m	96m	96m	98m	102m	105m	118m	118m	118m	119m	120m	122m	123m	124m	139m	139m
Filing	10-K	10-Q	10-Q	10-Q	10-K	10-Q	10-Q	10-Q	10-K	10-Q	10-Q	10-Q	10-K	10-Q	10-Q	10-Q	10-K	10-Q	10-Q	10-Q

Each quarter as filed, linked to its filing.

* The fourth quarter is the full year less the first three quarters, because the company files the year and not the quarter on its own. A fourth quarter's EPS, and its diluted share count where shown, are from the company's results press release for that quarter, checked against the company's filed figures or a second data source. A blank figure marked on a quarter is one the filings do not give on their own: the quarters as filed do not add to the year the company filed, or the year and its quarters stand on different share counts. Each quarter's page says which. A quarter marked † is shown as the company last restated it in a later filing, so it compares with the quarters around it on one basis; rest on a figure for the one first filed. EPS is as filed. Money is in $ million as the company files it, or in $ billion by the switch above the tables; per share figures and the share count are as they are. Free cash flow is operating cash flow less capital expenditure; the effective tax rate is income tax over pre-tax income; margins are the line over revenue. Gross profit is revenue less cost of revenue, and operating income is revenue less the company's own total costs, where the statement does not print those lines. Cash flow lines filed year to date are the difference between two filings. Shares outstanding are at the period end where the balance sheet tags them, otherwise the count on the filing's cover page. A derived fourth-quarter EPS is left blank when a split in the year makes the arithmetic meaningless.

10-Q for the period ended 30 September 2026, filed 4 November 2026: the filing.